The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while other cells over proliferate

Mutation Research - Reviews in Mutation Research

Volumn 759, Issue 1, 2014, Pages 40-48

  Krejci, Pavel ^a,b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Achondroplasia; Cancer; ERK; FGFR3; RASopathies; Skeletal dyplasia

Indexed keywords

FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN;

BONE DEVELOPMENT; BONE DYSPLASIA; BONE TUMOR; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; GENETICS; GERMLINE MUTATION; HUMAN; METABOLISM; ONCOGENE RAS; PATHOLOGY; SIGNAL TRANSDUCTION; ACHONDROPLASIA; ALLELE; BONE GROWTH; CARDIOFACIOCUTANEOUS SYNDROME; CELL CYCLE G1 PHASE; CELL GROWTH; COSTELLO SYNDROME; DNA REPLICATION; DWARFISM; FIBROBLAST; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GINGIVA FIBROMATOSIS; GROWTH PLATE; LEGIUS SYNDROME; LEOPARD SYNDROME; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; NOONAN SYNDROME; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SHORT STATURE; SOMATIC MUTATION; SPONTANEOUS MUTATION; UPREGULATION;

BONE DEVELOPMENT; BONE DISEASES, DEVELOPMENTAL; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROCYTES; GENES, RAS; GERM-LINE MUTATION; HUMANS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 84894250296     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2013.11.001     Document Type: Review

References (148)

1. Horton W.A., Hall J.G., Hecht J.T. Achondroplasia. Lancet 2007, 370:162-172.
2. Rousseau F., Bonaventure J., Legeai-Mallet L., Schmidt H., Weissenbach J., Maroteaux P., Munnich A., Le Merrer M. Clinical and genetic heterogeneity of hypochondroplasia. J. Med. Genet. 1996, 33:749-752.
3. Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T., Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J., Francomano C.A. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am. J. Hum. Genet. 2000, 67:1411-1421.
4. Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J., Donoghue D.J., Thompson L.M., Francomano C.A. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am. J. Hum. Genet. 1999, 64:722-731.
5. Maroteaux P., Lamy M., Robert J.M. Thanatophoric dwarfism. Presse Med. 1967, 75:2519-2524.
6. Naski M.C., Wang Q., Xu J., Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 1996, 13:233-237.
7. Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A., Thompson L.M., Bryja V., Kozubik A., Wilcox W.R. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS ONE 2008, 3:e3961.
8. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 1999, 23:18-20.
9. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M., Bergsagel P.L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 1997, 16:260-264.
10. Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E., Wilkie A.O. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet. 2009, 41:1247-1252.
11. Hafner C., Vogt T., Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 2006, 5:2723-2728.
12. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., Radvanyi F. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 2005, 14:1153-1160.
13. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
14. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
15. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., Hawley R.G., Stewart A.K. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000, 95:992-998.
16. Zhu L., Somlo G., Zhou B., Shao J., Bedell V., Slovak M.L., Liu X., Luo J., Yen Y. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol. Cancer Ther. 2005, 4:787-798.
17. Hafner C., Di Martino E., Pitt E., Stempfl T., Tomlinson D., Hartmann A., Landthaler M., Knowles M., Vogt T. FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp. Cell Res. 2010, 316:2008-2016.
18. di Martino E., L'Hote C.G., Kennedy W., Tomlinson D.C., Knowles M.A. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009, 28:4306-4316.
19. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
20. Li Z., Zhu Y.X., Plowright E.E., Bergsagel P.L., Chesi M., Patterson B., Hawley T.S., Hawley R.G., Stewart A.K. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001, 97:2413-2419.
21. Foldynova-Trantirkova S., Wilcox W.R., Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat. 2012, 33:29-41.
22. Bellus G.A., Hefferon T.W., Ortiz de Luna R.I., Hecht J.T., Horton W.A., Machado M., Kaitila I., McIntosh I., Francomano C.A. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet. 1995, 56:368-373.
23. Price C.T. Limb lengthening for achondroplasia: early experience. J. Pediatr. Orthop. 1989, 9:512-515.
24. Tanaka H., Kubo T., Yamate T., Ono T., Kanzaki S., Seino Y. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. Eur. J. Endocrinol. 1998, 138:275-280.
25. Shohat M., Tick D., Barakat S., Bu X., Melmed S., Rimoin D.L. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J. Clin. Endocrinol. Metab. 1996, 81:4033-4037.
26. Tanaka N., Katsumata N., Horikawa R., Tanaka T. The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr. J. 2003, 50:69-75.
27. Kanazawa H., Tanaka H., Inoue M., Yamanaka Y., Namba N., Seino Y. Efficacy of growth hormone therapy for patients with skeletal dysplasia. J. Bone Miner. Metab. 2003, 21:307-310.
28. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-960.
29. Liang G., Liu Z., Wu J., Cai Y., Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci. 2012, 33:531-541.
30. Bello E., Colella G., Scarlato V., Oliva P., Berndt A., Valbusa G., Serra S.C., D'Incalci M., Cavalletti E., Giavazzi R., Damia G., Camboni G. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71:1396-1405.
31. Chase A., Grand F.H., Cross N.C. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007, 110:3729-3734.
32. Scagliotti G.V., Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat. Rev. 2012, 38:292-302.
33. Bukowski R.M., Yasothan U., Kirkpatrick P. Pazopanib. Nat. Rev. Drug Discov. 2010, 9:17-18.
34. Keisner S.V., Shah S.R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71:443-454.
35. Pejchalova K., Krejci P., Wilcox W.R. C-natriuretic peptide: an important regulator of cartilage. Mol. Genet. Metab. 2007, 92:210-215.
36. Kronenberg H.M. PTHrP and skeletal development. Ann. N.Y. Acad. Sci. 2006, 1068:1-13.
37. Yamanaka Y., Ueda K., Seino Y., Tanaka H. Molecular basis for the treatment of achondroplasia. Horm. Res. 2003, 60(Suppl. 3):60-64.
38. Chen L., Li C., Qiao W., Xu X., Deng C. A Ser(365)→Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum. Mol. Genet. 2001, 10:457-465.
39. Ueda K., Yamanaka Y., Harada D., Yamagami E., Tanaka H., Seino Y. PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone 2007, 41:13-18.
40. Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 2005, 17:215-224.
41. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
42. Dell'Era P., Mohammadi M., Presta M. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Mol. Biol. Cell 1999, 10:23-33.
43. Boilly B., Vercoutter-Edouart A.S., Hondermarck H., Nurcombe V., Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 2000, 11:295-302.
44. Lovicu F.J., McAvoy J.W. FGF-induced lens cell proliferation and differentiation is dependent on MAPK (ERK1/2) signalling. Development 2001, 128:5075-5084.
45. Portnoy J., Curran-Everett D., Mason R.J. Keratinocyte growth factor stimulates alveolar type II cell proliferation through the extracellular signal-regulated kinase and phosphatidylinositol 3-OH kinase pathways. Am. J. Respir. Cell Mol. Biol. 2004, 30:901-907.
46. Garcia-Maya M., Anderson A.A., Kendal C.E., Kenny A.V., Edwards-Ingram L.C., Holladay A., Saffell J.L. Ligand concentration is a driver of divergent signaling and pleiotropic cellular responses to FGF. J. Cell Physiol. 2006, 206:386-393.
47. Vogel S., Kubin T., von der Ahe D., Deindl E., Schaper W., Zimmermann R. MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells. J. Cell Physiol. 2006, 206:25-34.
48. Kalluri H.S., Vemuganti R., Dempsey R.J. Mechanism of insulin-like growth factor I-mediated proliferation of adult neural progenitor cells: role of Akt. Eur. J. Neurosci. 2007, 25:1041-1048.
49. Mojsilovic S., Krstic A., Ilic V., Okic-Dordevic I., Kocic J., Trivanovic D., Santibanez J.F., Jovcic G., Bugarski D. IL-17 and FGF signaling involved in mouse mesenchymal stem cell proliferation. Cell Tissue Res. 2011, 346:305-316.
50. Takahashi M., Okubo N., Chosa N., Takahashi N., Ibi M., Kamo M., Mizuki H., Ishisaki A., Kyakumoto S. Fibroblast growth factor-1-induced ERK1/2 signaling reciprocally regulates proliferation and smooth muscle cell differentiation of ligament-derived endothelial progenitor cell-like cells. Int. J. Mol. Med. 2012, 29:357-364.
51. Kang S., Dong S., Gu T.L., Guo A., Cohen M.S., Lonial S., Khoury H.J., Fabbro D., Gilliland D.G., Bergsagel P.L., Taunton J., Polakiewicz R.D., Chen J. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007, 12:201-214.
52. Yadav V., Zhang X., Liu J., Estrem S., Li S., Gong X.Q., Buchanan S., Henry J.R., Starling J.J., Peng S.B. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 2012, 287:28087-28098.
53. Agazie Y.M., Movilla N., Ischenko I., Hayman M.J. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 2003, 22:6909-6918.
54. Ishikawa H., Tsuyama N., Liu S., Abroun S., Li F.J., Otsuyama K., Zheng X., Ma Z., Maki Y., Iqbal M.S., Obata M., Kawano M.M. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 2005, 24:6328-6332.
55. Krejci P., Bryja V., Pachernik J., Hampl A., Pogue R., Mekikian P., Wilcox W.R. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp. Cell Res. 2004, 297:152-164.
56. Krejci P., Masri B., Fontaine V., Mekikian P.B., Weis M., Prats H., Wilcox W.R. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. Cell Sci. 2005, 118:5089-5100.
57. Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H., Thompson L.M., Wilcox W.R. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J. Biol. Chem. 2007, 282:2929-2936.
58. Krejci P., Salazar L., Goodridge H.S., Kashiwada T.A., Schibler M.J., Jelinkova P., Thompson L.M., Wilcox W.R. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J. Cell Sci. 2008, 121:272-281.
59. Raucci A., Laplantine E., Mansukhani A., Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem. 2004, 279:1747-1756.
60. Nowroozi N., Raffioni S., Wang T., Apostol B.L., Bradshaw R.A., Thompson L.M. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum. Mol. Genet. 2005, 14:1529-1538.
61. Yasoda A., Komatsu Y., Chusho H., Miyazawa T., Ozasa A., Miura M., Kurihara T., Rogi T., Tanaka S., Suda M., Tamura N., Ogawa Y., Nakao K. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat. Med. 2004, 10:80-86.
62. Dailey L., Laplantine E., Priore R., Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J. Cell Biol. 2003, 161:1053-1066.
63. Murakami S., Balmes G., McKinney S., Zhang Z., Givol D., de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 2004, 18:290-305.
64. Matsushita T., Wilcox W.R., Chan Y.Y., Kawanami A., Bukulmez H., Balmes G., Krejci P., Mekikian P.B., Otani K., Yamaura I., Warman M.L., Givol D., Murakami S. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum. Mol. Genet. 2009, 18:227-240.
65. Aikawa T., Segre G.V., Lee K. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J. Biol. Chem. 2001, 276:29347-29352.
66. Koziczak M., Holbro T., Hynes N.E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004, 23:3501-3508.
67. Tomlinson D.C., Lamont F.R., Shnyder S.D., Knowles M.A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 2009, 69:4613-4620.
68. Pumiglia K.M., Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:448-452.
69. Decker S.J. Nerve growth factor-induced growth arrest and induction of p21Cip1/WAF1 in NIH-3T3 cells expressing TrkA. J. Biol. Chem. 1995, 270:30841-30844.
70. Sewing A., Wiseman B., Lloyd A.C., Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell Biol. 1997, 17:5588-5597.
71. Roovers K., Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000, 22:818-826.
72. Tidyman W.E., Rauen K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 2009, 19:230-236.
73. Chardin P., Camonis J.H., Gale N.W., van Aelst L., Schlessinger J., Wigler M.H., Bar-Sagi D. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993, 260:1338-1343.
74. Gibbs J.B., Schaber M.D., Allard W.J., Sigal I.S., Scolnick E.M. Purification of ras GTPase activating protein from bovine brain. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5026-5030.
75. Xu G.F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62:599-608.
76. Wakioka T., Sasaki A., Kato R., Shouda T., Matsumoto A., Miyoshi K., Tsuneoka M., Komiya S., Baron R., Yoshimura A. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001, 412:647-651.
77. Stowe I.B., Mercado E.L., Stowe T.R., Bell E.L., Oses-Prieto J.A., Hernandez H., Burlingame A.L., McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012, 26:1421-1426.
78. Stevenson D.A., Yang F.C. The musculoskeletal phenotype of the RASopathies. Am. J. Med. Genet. C: Semin. Med. Genet. 2011, 157:90-103.
79. Urosevic J., Sauzeau V., Soto-Montenegro M.L., Reig S., Desco M., Wright E.M., Canamero M., Mulero F., Ortega S., Bustelo X.R., Barbacid M. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5015-5020.
80. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., Yang W., Pao L.I., Gilliland D.G., Epstein J.A., Neel B.G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 2004, 10:849-857.
81. Chen P.C., Wakimoto H., Conner D., Araki T., Yuan T., Roberts A., Seidman C., Bronson R., Neel B., Seidman J.G., Kucherlapati R. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J. Clin. Invest. 2010, 120:4353-4365.
82. Ono K., Karolak M.R., Ndong J.D., Wang W., Yang X., Elefteriou F. The Ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation. Hum. Mol. Genet. 2013, 22(15):3048-3062.
83. Peters K., Ornitz D., Werner S., Williams L. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol. 1993, 155:423-430.
84. Schubbert S., Zenker M., Rowe S.L., Boll S., Klein C., Bollag G., van der Burgt I., Musante L., Kalscheuer V., Wehner L.E., Nguyen H., West B., Zhang K.Y., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., Kratz C.P. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 2006, 38:331-336.
85. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006, 311:1287-1290.
86. Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., Hennekam R.C., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., Matsubara Y. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 2006, 38:294-296.
87. Gripp K.W. Tumor predisposition in Costello syndrome. Am. J. Med. Genet. C: Semin. Med. Genet. 2005, 137C:72-77.
88. Aoki Y., Niihori T., Narumi Y., Kure S., Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum. Mutat. 2008, 29:992-1006.
89. Kratz C.P., Rapisuwon S., Reed H., Hasle H., Rosenberg P.S. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am. J. Med. Genet. C: Semin. Med. Genet. 2011, 157:83-89.
90. Johnson N.L., Gardner A.M., Diener K.M., Lange-Carter C.A., Gleavy J., Jarpe M.B., Minden A., Karin M., Zon L.I., Johnson G.L. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J. Biol. Chem. 1996, 271:3229-3237.
91. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998, 12:2997-3007.
92. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
93. Cagnol S., Chambard J.C. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J. 2010, 277:2-21.
94. Su W.C., Kitagawa M., Xue N., Xie B., Garofalo S., Cho J., Deng C., Horton W.A., Fu X.Y. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 1997, 386:288-292.
95. Krejci P., Prochazkova J., Smutny J., Chlebova K., Lin P., Aklian A., Bryja V., Kozubik A., Wilcox W.R. FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone 2010, 47:102-110.
96. Ota S., Zhou Z.Q., Link J.M., Hurlin P.J. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum. Mol. Genet. 2009, 18:2609-2621.
97. Trost T.M., Lausch E.U., Fees S.A., Schmitt S., Enklaar T., Reutzel D., Brixel L.R., Schmidtke P., Maringer M., Schiffer I.B., Heimerdinger C.K., Hengstler J.G., Fritz G., Bockamp E.O., Prawitt D., Zabel B.U., Spangenberg C. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 2005, 65:840-849.
98. Sperandio S., Poksay K., de Belle I., Lafuente M.J., Liu B., Nasir J., Bredesen D.E. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ. 2004, 11:1066-1075.
99. Burns T.F., Dobromilskaya I., Murphy S.C., Gajula R.P., Thiyagarajan S., Chatley S.N., Aziz K., Cho Y.J., Tran P.T., Rudin C.M. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Mol. Cancer Res. 2013, 11:329-338.
100. Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R., Wright P.E., Han J. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308.
101. Yaswen P., Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007, 128:233-234.
102. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
103. Ha L., Ichikawa T., Anver M., Dickins R., Lowe S., Sharpless N.E., Krimpenfort P., Depinho R.A., Bennett D.C., Sviderskaya E.V., Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10968-10973.
104. Ho J.H., Chen Y.F., Ma W.H., Tseng T.C., Chen M.H., Lee O.K. Cell contact accelerates replicative senescence of human mesenchymal stem cells independent of telomere shortening and p53 activation: roles of Ras and oxidative stress. Cell Transplant. 2011, 20:1209-1220.
105. Deschenes-Simard X., Gaumont-Leclerc M.F., Bourdeau V., Lessard F., Moiseeva O., Forest V., Igelmann S., Mallette F.A., Saba-El-Leil M.K., Meloche S., Saad F., Mes-Masson A.M., Ferbeyre G. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 2013, 27:900-915.
106. Kolupaeva V., Basilico C. Overexpression of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest in the presence of hypophosphorylated Rb proteins. Cell Cycle 2012, 11:2557-2566.
107. Legeai-Mallet L., Benoist-Lasselin C., Munnich A., Bonaventure J. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 2004, 34:26-36.
108. Chen L., Adar R., Yang X., Monsonego E.O., Li C., Hauschka P.V., Yayon A., Deng C.X. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 1999, 104:1517-1525.
109. Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., Deng C.X. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 1999, 8:35-44.
110. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
111. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Beach D., Serrano M. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
112. Lynch M. Rate, molecular spectrum, and consequences of human mutation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:961-968.
113. Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell Biol. 2000, 20:516-522.
114. Delezoide A.L., Benoist-Lasselin C., Legeai-Mallet L., Le Merrer M., Munnich A., Vekemans M., Bonaventure J. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech. Dev. 1998, 77:19-30.
115. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 2012, 66:105-143.
116. Shen J., Zhang J., Luo X., Zhu W., Yu K., Chen K., Li Y., Jiang H. Predicting protein-protein interactions based only on sequences information. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4337-4341.
117. Yudoh K., Shi Y., Karasawa R. Angiogenic growth factors inhibit chondrocyte ageing in osteoarthritis: potential involvement of catabolic stress-induced overexpression of caveolin-1 in cellular ageing. Int. J. Rheum. Dis. 2009, 12:90-99.
118. Cho K.A., Ryu S.J., Park J.S., Jang I.S., Ahn J.S., Kim K.T., Park S.C. Senescent phenotype can be reversed by reduction of caveolin status. J. Biol. Chem. 2003, 278:27789-27795.
119. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
120. Roring M., Brummer T. Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit. Rev. Oncog. 2012, 17:97-121.
121. Murugan A.K., Munirajan A.K., Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012, 48:383-392.
122. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
123. Santarpia L., Lippman S.M., El-Naggar A.K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:103-119.
124. Brodie S.G., Deng C.X. Mouse models orthologous to FGFR3-related skeletal dysplasias. Pediatr. Pathol. Mol. Med. 2003, 22:87-103.
125. Bartels C.F., Bukulmez H., Padayatti P., Rhee D.K., van Ravenswaaij-Arts C., Pauli R.M., Mundlos S., Chitayat D., Shih L.Y., Al-Gazali L.I., Kant S., Cole T., Morton J., Cormier-Daire V., Faivre L., Lees M., Kirk J., Mortier G.R., Leroy J., Zabel B., Kim C.A., Crow Y., Braverman N.E., van den Akker F., Warman M.L. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet. 2004, 75:27-34.
126. Passos-Bueno M.R., Wilcox W.R., Jabs E.W., Sertie A.L., Alonso L.G., Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 1999, 14:115-125.
127. Stein G.H., Drullinger L.F., Robetorye R.S., Pereira-Smith O.M., Smith J.R. Senescent cells fail to express cdc2, cycA, and cycB in response to mitogen stimulation. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:11012-11016.
128. Wang W., Chen J.X., Liao R., Deng Q., Zhou J.J., Huang S., Sun P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol. Cell Biol. 2002, 22:3389-3403.
129. Zhang R., Murakami S., Coustry F., Wang Y., de Crombrugghe B. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:365-370.
130. Fukami J., Anno K., Ueda K., Takahashi T., Ide T. Enhanced expression of cyclin D1 in senescent human fibroblasts. Mech. Ageing Dev. 1995, 81:139-157.
131. Benvenuti S., Cramer R., Bruce J., Waterfield M.D., Jat P.S. Identification of novel candidates for replicative senescence by functional proteomics. Oncogene 2002, 21:4403-4413.
132. Benanti J.A., Williams D.K., Robinson K.L., Ozer H.L., Galloway D.A. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol. Cell Biol. 2002, 22:7385-7397.
133. Park W.Y., Park J.S., Cho K.A., Kim D.I., Ko Y.G., Seo J.S., Park S.C. Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J. Biol. Chem. 2000, 275:20847-20852.
134. Barradas M., Gonos E.S., Zebedee Z., Kolettas E., Petropoulou C., Delgado M.D., Leon J., Hara E., Serrano M. Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp. Cell Res. 2002, 273:127-137.
135. Gonos E.S., Derventzi A., Kveiborg M., Agiostratidou G., Kassem M., Clark B.F., Jat P.S., Rattan S.I. Cloning and identification of genes that associate with mammalian replicative senescence. Exp. Cell Res. 1998, 240:66-74.
136. Hara E., Yamaguchi T., Nojima H., Ide T., Campisi J., Okayama H., Oda K. Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J. Biol. Chem. 1994, 269:2139-2145.
137. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
138. Guo C., Degnin C.R., Laederich M.B., Lunstrum G.P., Holden P., Bihlmaier J., Krakow D., Cho Y.J., Horton W.A. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal 2008, 20:1471-1477.
139. Li Q., Tang L., Roberts P.C., Kraniak J.M., Fridman A.L., Kulaeva O.I., Tehrani O.S., Tainsky M.A. Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol. Cancer Res. 2008, 6:770-784.
140. Krejci P., Prochazkova J., Bryja V., Jelinkova P., Pejchalova K., Kozubik A., Thompson L.M., Wilcox W.R. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal. 2009, 21:151-160.
141. Itahana K., Campisi J., Dimri G.P. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol. Biol. 2007, 371:21-31.
142. Martin M., el Nabout R., Lafuma C., Crechet F., Remy J. Fibronectin and collagen gene expression during in vitro ageing of pig skin fibroblasts. Exp. Cell Res. 1990, 191:8-13.
143. Ornoy A., Adomian G.E., Eteson D.J., Burgeson R.E., Rimoin D.L. The role of mesenchyme-like tissue in the pathogenesis of thanatophoric dysplasia. Am. J. Med. Genet. 1985, 21:613-630.
144. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
145. Parrinello S., Coppe J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci. 2005, 118:485-496.
146. Krtolica A., Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol. 2002, 34:1401-1414.
147. Ota H., Tokunaga E., Chang K., Hikasa M., Iijima K., Eto M., Kozaki K., Akishita M., Ouchi Y., Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25:176-185.
148. Brenner R.E., Nerlich A., Terinde R., Bartmann P. In vitro studies on clonal growth of chondrocytes in thanatophoric dysplasia. Am. J. Med. Genet. 1996, 63:401-405.